Dr. Ataman succeeds Dr. Seppo Pakkala in this position. Dr. Pakkala continues to serve on the Board of Directors and advises Tenboron on medical topics.

The first patients have received BNCT treatment at the HUS Comprehensive Cancer Center in Helsinki, Finland:

https://www.hus.fi/en/newsroom/bnct-treatments-cancer-patients-have-started-part-clinical-trial

Dr. Ataman is specialized in clinical radiation related research with technical and in depth understanding of radiation biology and physics as well as clinical endpoints and passionate on improving oncology outcomes. She will play a central role in the team that plans and executes Tenboron’s clinical program.

The first patient has enrolled in the Phase I clinical trial and was dosed on Sunday, April 14. No acute safety issues were reported.

Tenboron’s background and BNCT technology are presented in this post:

https://www.suomenbioteollisuus.fi/post/finnish-company-tenboron-develops-groundbreaking-cancer-treatment

Study preparations have been completed and necessary permits obtained.

Data from the first patient(s) expected in Q1/2024.